BioXcel Therapeutics is trading 9.04% down at $0.17 after its August 27 Chapter 11 filing and Teva’s stalking-horse bid for substantially all assets.
- Reuters reported the filing on August 28; Teva’s proposed transaction provides $57.5 million upfront plus potential milestone payments, leaving the sale subject to higher bids.
- The pre-market decline follows the August 28 close of $0.18, down 74.76%.
- Bankruptcy-related uncertainty and liquidation/restructuring pressure are clearest company-specific catalysts; broader markets are mixed, making macro sentiment secondary.